ADMA Biologics: Culper Research Alleges Channel Stuffing on 20% Revenue Growth
The short seller says revenue declined 3%. The 10-K says it grew 20%. The CEO is buying shares. The CFO is leaving. Five lenses, zero certainty.
20% YoY growth (audited by KPMG)
51% YoY growth, 70% of total revenue
2 customers hold 87% of receivables
Following Culper Research short report
ADMA Biologics has become the most contested name in biotech after Culper Research published a short report alleging the company fabricated its 20% revenue growth through channel stuffing and undisclosed related-party sales. The stock crashed 29%. Securities fraud investigations followed. Management responded by accelerating a $125 million share buyback.
The difficulty in parsing this situation is that the bull and bear cases operate on different metrics. The bull case rests on audited product-level revenue: ASCENIV, ADMA's specialty immune globulin, generated $363 million in FY2025 revenue with 51% year-over-year growth. The bear case rests on working capital metrics: two customers hold 87% of accounts receivable, and management acknowledged that days sales outstanding need to “improve.”
Both cases can be simultaneously correct. Revenue can be real and the channel can be overstocked. Our 5-lens committee analysis attempts to determine which version of reality the data supports.
Want the full 5-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 5 lenses. 8 signals. 7 debates. Full evidence citations from SEC filings.
Signal Assessments
87% AR concentration in 2 customers with rising DSO. KPMG audit is clean, but audits verify methodology, not sell-through.
ASCENIV at 51% growth with real clinical differentiation, but channel inventory normalization is unverified.
CEO is net buyer (+98,927 shares). But Director sold $9.3M, and CFO departed during controversy.
Bull case ($1.1B by 2029) and bear case (-3% actual revenue) are nearly irreconcilable.
$88M cash with $231M adjusted EBITDA. Company is profitable and not capital-markets dependent.
$200M buyback funded from operations. Plasma center divestiture demonstrates capital recycling discipline.
At 6.7x trailing revenue post-crash, market has partially discounted controversy. Re-rating depends on DSO trends.
FDA lot releases continuing normally. No enforcement actions. Securities investigations are plaintiff-driven, not regulatory.
Key Findings
Bull and Bear Cases Operate on Different Metrics
The most important insight from this analysis: the short seller alleges fabricated revenue, but the more precise claim may be that revenue quality is lower than headline numbers suggest. Revenue can be properly recognized under ASC 606, audited by KPMG, and still represent channel loading rather than end-patient demand. A company can simultaneously report genuine revenue AND have an overstocked channel. Investors who frame this as binary (fraud vs. no fraud) may miss the middle ground.
87% AR Concentration Creates Unverifiable Channel Dynamics
BioCare and CuraScript hold 87% of ADMA's accounts receivable. This concentration means that inventory levels at just two entities determine the health of ADMA's entire revenue base. From public filings alone, it is impossible to verify whether these distributors have sold through their inventory to end-patients or are sitting on excess stock. The McKesson distribution agreement is a direct response to this concentration risk, but it may temporarily introduce new channel-stocking noise as McKesson builds initial inventory.
CEO Net Accumulation Is the Strongest Counter-Signal
CEO Adam Grossman accumulated a net +98,927 shares through the controversy period via a 10b5-1 plan established on November 14, 2025. His total holdings exceed 2.1 million shares, representing approximately $31.5 million in personal exposure at current prices. Executives at companies committing wholesale fraud typically liquidate holdings, not accumulate them. This is the single strongest data point against the most extreme version of the short seller thesis.
Where Models Disagreed
Is AR Concentration Evidence of Channel Stuffing?
Adopted
Concentration reflects the structural reality of specialty pharmacy distribution. Two customers dominating is standard for niche biologics.
Withdrawn
87% AR concentration alone proves channel stuffing. (Refined to: concentration creates conditions where stuffing could occur undetected.)
Does the KPMG Audit Resolve Integrity Concerns?
Adopted
KPMG confirms revenue recognition compliance, which is meaningful. But auditors verify methodology, not whether distributors sold through their inventory.
Withdrawn
A Big 4 audit definitively disproves channel stuffing. (Revenue recognition compliance and demand verification are separate questions.)
Is the 29% Crash an Overreaction?
Adopted
The crash overreacted to the fraud narrative (likely overstated) but appropriately repriced revenue quality risk (which is real). Truth lies between extremes.
Withdrawn
The crash is clearly excessive given KPMG audit and CEO buying. (Unresolved DSO question prevents declaring it a definitive overreaction.)
Where Lenses Agree
ASCENIV's clinical differentiation is real
All five lenses found consistent evidence that ASCENIV is a genuinely differentiated product with published clinical data, sustained pricing power (5.5-6x premium), and expanding payer coverage.
The AR/DSO concern is legitimate even if fraud is overstated
The committee distinguishes between “the revenue is fake” (likely false) and “some revenue may be overearned through channel loading” (plausible). This nuance is often lost in the binary narrative.
CEO insider accumulation is the strongest counter-signal
Grossman's net +98,927 shares via pre-established 10b5-1 plan dramatically reduces the probability of the most extreme fraud claims. Executives committing fraud liquidate; they do not accumulate.
What to Watch
DSO above 90 days for two consecutive quarters would signal structural channel issues. This is the primary diagnostic for distinguishing between growth and loading.
Current investigations are plaintiff-driven (law firms, not SEC). An SEC formal investigation order would be a fundamentally different risk and would warrant immediate reassessment.
Q4 2025 revenue was $139.2M. If Q1 2026 drops below $130M, it may indicate channel digestion. If it grows, the growth narrative strengthens.
CEO Grossman's net buying is the strongest counter-signal to the fraud thesis. Any shift to net selling or modification of the 10b5-1 plan would be highly significant.
McKesson reaching greater than 15% of revenue by Q4 2026 would diversify the customer base and reduce the structural conditions enabling channel-loading concerns.
HIGHER SCRUTINY
The core ASCENIV product has real clinical differentiation and demand, and the short seller's claim of fabricated revenue is likely overstated. However, extreme customer concentration, rising DSO, a CFO departure, and concurrent investigations create a risk profile that demands closer monitoring than standard diligence. The committee does not find evidence sufficient for AVOID, but the unresolved working capital concerns preclude PROCEED WITH CAUTION.
Path to More Favorable Assessment
- • DSO normalizes below 75 days for 2 quarters
- • McKesson reaches greater than 15% of revenue, reducing customer concentration below 65%
- • Q1/Q2 2026 sequential revenue growth continues
- • CEO maintains net buying or increases accumulation
Path to Less Favorable Assessment
- • DSO exceeds 90 days for 2 consecutive quarters
- • SEC opens formal investigation
- • CEO shifts to net seller or modifies 10b5-1 plan
- • Q1 2026 revenue declines significantly from Q4 2025
- • Material restatement or KPMG issues qualified opinion
This analysis is for educational purposes only. It is not a recommendation to buy or sell any security.
Public Sources Used (18 documents)
- Annual Report (10-K) — FY2025
- Quarterly Reports (10-Q) — Q3 2025, Q2 2025, Q1 2025, Q3 2024
- Current Reports (8-K) — 10 filings, Mar 2025 - Mar 2026
- Form 4 Insider Transactions — 20 filings
- Form 144 Proposed Sales — 10 filings
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
- CourtListener Litigation Search — 10 cases
Full Analysis with Signal Breakdowns
Explore the complete 5-lens assessment including debate transcripts, evidence citations, stress scenarios, and monitoring triggers.
View ADMA Analysis